SCHEMBL2123510

SCHEMBL2123510

CC(C)Cn1c(=O)n(C)c(=N)c2c(Nc3ccccc3)n(Cc3ccc(-c4ccccn4)cc3)nc21

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE1B Q01064 4/20 0.56
PDE1A P54750 2/20 0.56
PDE1C Q14123 2/20 0.56
PDE4A P27815 12/20 0.47
PDE2A O00408 3/20 0.47
PDE8A O60658 2/20 0.47
PDE5A O76074 2/20 0.47
PDE3B Q13370 2/20 0.47
PDE11A Q9HCR9 2/20 0.47
PDE7B Q9NP56 2/20 0.47
PDE10A Q9Y233 2/20 0.47
PDE9A O76083 1/20 0.47
PDE4D Q08499 1/20 0.38
CDK4 P11802 1/20 0.36
CCND1 P24385 1/20 0.36
CCND2 P30279 1/20 0.36
CCND3 P30281 1/20 0.36
USP1 O94782 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL193938 0.92 PDE1B (0.66) PDE1BPDE1APDE1CPDE4APDE2A
SCHEMBL2119817 0.90 PDE1B (0.56) PDE1BPDE1APDE1CPDE4APDE2A
SCHEMBL2121446 0.89 PDE1B (0.55) PDE1BPDE1APDE1CPDE4APDE2A
SCHEMBL2612339 0.89 PDE1B (0.55) PDE1BPDE1APDE1CPDE4APDE2A
SCHEMBL2121444 0.89 PDE1B (0.55) PDE1BPDE1APDE1CPDE4APDE2A
SCHEMBL8045653 0.85 PDE1B (0.59) PDE1BPDE1APDE1CPDE4APDE2A
SCHEMBL194834 0.85 PDE1B (0.58) PDE1BPDE1APDE1CPDE4APDE2A
SCHEMBL194833 0.85 PDE1B (0.58) PDE1BPDE1APDE1CPDE4APDE2A
SCHEMBL3008702 0.85 PDE1B (0.58) PDE1BPDE1APDE1CPDE4APDE2A
SCHEMBL3008705 0.85 PDE1B (0.58) PDE1BPDE1APDE1CPDE4APDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2367431-B1 ORGANIC COMPOUNDS INTRA CELLULAR THERAPIES INC (US) 2015-08-05 EP disclosed
US-20140315868-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES, INC. (US) 2014-10-23 US disclosed
US-8697710-B2 Optionally substituted 3-amino-4-(thioxo or imino)-4,5-dihydro-2H-pyrazolo [3,4-d]pyrimidin-6(7H)-ones INTRA-CELLULAR THERAPIES, INC. (US) 2014-04-15 US disclosed
US-20120094966-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES, INC. 2012-04-19 US disclosed
EP-2367431-A1 ORGANIC COMPOUNDS Intra-Cellular Therapies, Inc. (US) 2011-09-28 EP disclosed
WO-2010065153-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES, INC. (US) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315868-A1 ORGANIC COMPOUNDS TPMT, CYP4X1, P2RX4 PDE1B 4847/4885PDE1A 4868/4885PDE1C 4824/4885
US-20120094966-A1 ORGANIC COMPOUNDS TPMT, CYP4X1, P2RX4 PDE1B 4847/4885PDE1A 4868/4885PDE1C 4824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.